lead plaintiff deadline

Rosen Law Firm files securities class actions against Nektar Therapeutics, Enphase Energy, and Aquestive Therapeutics. Investors have until May 5, 2026 to join.

Rosen Law Firm filed securities class action against Enphase Energy ($ENPH) alleging false statements on inventory and renewable energy credits. Deadline April 20, 2026.

Class action lawsuit filed against $APO alleging leadership made false statements about Jeffrey Epstein business dealings. Eligible investors purchased securities between May 2021 and February 2026.

Class action lawsuit filed against $METC alleges executives made false statements about Brook Mine development progress. Investors from July-October 2025 urged to participate.

REGENXBIO faces securities lawsuit over alleged misleading RGX-111 gene therapy statements. Lead plaintiff deadline is April 14, 2026.

Rosen Law Firm urges $BBWI investors to join class action by March 16, 2026 deadline, alleging materially false statements about business strategy and unmet financial guidance.

Rosen Law Firm solicits Beyond Meat investors from Feb-Nov 2025 for class action alleging material asset value misstatements and impairment disclosure failures.

BellRing Brands faces securities lawsuit alleging it misrepresented sales growth as organic when driven by inventory stockpiling, with a March 23, 2026 deadline for investors to join.

Rosen Law Firm alerts $SNOW investors of April 27, 2026 deadline in class action alleging undisclosed negative impacts from product efficiency gains.

uniQure faces securities lawsuit after FDA rejected AMT-130 approval pathway. Stock plummeted 49% following disclosure. Lead plaintiff deadline: April 13, 2026.

Kyndryl Holdings faces securities class action over undisclosed internal control weaknesses. Stock plunged 55% after February 2026 disclosure; lead plaintiff deadline set for April 13.

Enphase Energy faces class action lawsuit over alleged material misstatements regarding inventory management and tax credit impacts. Lead plaintiff deadline set for April 20, 2026.

$CORT stock plummets 50% after FDA rejects lead drug relacorilant; class action targets alleged disclosure failures with lead plaintiff deadline April 21, 2026.

Navan investors face April 24, 2026 deadline to file lead plaintiff applications in class action over undisclosed $95M sales/marketing expense surge in Q3 2025.

Apollo Global Management faces class action over alleged Epstein executive communications non-disclosure. Investors with $100,000+ losses must apply as lead plaintiffs by May 1, 2026.

Soleno Therapeutics faces class action lawsuit alleging material safety concerns about DCCR drug were hidden from investors. Lead plaintiff deadline is May 5, 2026.

BellRing Brands faces securities class action alleging material disclosure failures from November 2024–August 2025, with stock declines of 19% and 33% following disappointing guidance.

Rosen Law Firm sued Richtech Robotics for allegedly misrepresenting a Microsoft partnership. Investors must file claims by April 3, 2026.

Rosen Law Firm notifies $CORT investors of securities class action alleging misrepresentation of clinical trial data for relacorilant drug and undisclosed FDA concerns.

Rosen Law Firm files securities class action against Franklin BSP Realty Trust alleging false statements. Investors must act before lead plaintiff deadline.